Annual report pursuant to Section 13 and 15(d)

Shareholders' Equity (Details) - Schedule of stock-based compensation expense

v3.22.1
Shareholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Schedule of stock-based compensation expense [Abstract]    
Research and development options expense $ 304,421 $ 252,173
Total research and development expenses 304,421 252,173
General and administrative options expense 1,955,096 1,168,281
Stock and warrants issued to consultants and employees 1,980,900 710,792
Total general and administrative expenses 3,935,996 1,879,073
Total stock-based compensation expense $ 4,240,417 $ 2,131,246